Clinical trial
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug…
NCT00306475 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00306475 |
|---|---|
| Title | Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? |
| Official title | Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Alliance for Research on Schizophrenia and Depression Abbott Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Divalproex Sodium Extended-Release Tablets, placebo |
| Enrollment | 60 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Mar 23, 2006 |
| Last update posted | Jun 27, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: